K. Mross

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Simone Steinbild, K. Mross, Annette Frost et al. · British Journal of Cancer · 2007 · 101 citations · Full text

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors

K. Mross, Simone Steinbild, Frank Baas et al. · International Journal of Clinical Pharmacology and Therapeutics · 2003 · 23 citations

Oncology, Solid Tumors, Medicine +7

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

Bruno Morgan, Anne Thomas, Joachim Drevs et al. · Journal of Clinical Oncology · 2003 · 21 citations

Phase I Clinical Trial of Lobaplatin (D-19466) after Intravenous Bolus Injection

H.H. Fiebig, H. Henß, K. Mross et al. · Oncology Research and Treatment · 1994 · 18 citations

Hematological Malignancy, Medicine, Malignant Blood Disorder +12

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC)

Dirk Strumberg, M. E. Scheulen, Annette Frost et al. · Journal of Clinical Oncology · 2009 · 14 citations

Pathology, Pharmacotherapy, Tumor Biology +18